Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu®-resistance Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103 LONDON and PHILADELPHIA, Oct. 23, 2026 ( …